Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

NCT05999604 is registered in ClinicalTrials.gov with Fondation Ophtalmologique Adolphe de Rothschild as lead sponsor.

NCT NCT05999604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05999604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 9, 2023
Completion date
May 31, 2028
Enrollment
244 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis